GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Immunogenicity & Safety Study of a Meningococcal Serogroup B Vaccine Given in a 3 Dose Schedule to Healthy Adolescents Aged 12-18 Yrs
Phase 2
Completed
- Conditions
- Infections, Meningococcal
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 478
- Registration Number
- NCT00137917
Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m
Phase 3
Completed
- Conditions
- Haemophilus Influenzae Type bDiphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis VaccinWhole Cell PertussisHepatitis BDiphtheriaTetanus
- Interventions
- Biological: Tritanrix-HepB/Hib-MenACBiological: Mencevax ACWYBiological: Tritanrix-HepB/HiberixBiological: Meningitec
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 617
- Registration Number
- NCT00136604
- Locations
- 🇹🇭
GSK Investigational Site, Songkla, Thailand
SB-743921 In Patients With Solid Tumors
Phase 1
Completed
- Conditions
- Solid Tumor Cancer
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT00136513
- Locations
- 🇺🇸
GSK Investigational Site, Madison, Wisconsin, United States
Ispinesib In Combination With Carboplatin In Patients With Solid Tumors
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT00136578
- Locations
- 🇬🇧
GSK Investigational Site, Newcastle Upon Tyne, Northumberland, United Kingdom
Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT Vaccine and Hib-MenC-TT Vaccine in Infants
Phase 2
Completed
- Conditions
- Infections, Meningococcal
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 500
- Registration Number
- NCT00135486
Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy Toddlers
Phase 2
Completed
- Conditions
- Infections, Meningococcal
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 500
- Registration Number
- NCT00135564
Study Of 323U66 SR In Major Depressive Disorder
Phase 2
Completed
- Conditions
- Depressive Disorder
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2019-02-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 234
- Registration Number
- NCT00135512
- Locations
GSK Investigational Site
Study Of Generalized Anxiety Disorder
Phase 2
Completed
- Conditions
- Anxiety DisorderAnxiety Disorders
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2011-01-31
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00135525
Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines
Phase 2
Completed
- Conditions
- Haemophilus Influenzae Type bNeisseria Meningitidis
- Interventions
- Biological: MenHibrix (Hib-MenCY-TT)Biological: Infanrix® PentaBiological: Prevenar®Biological: ActHIB®Biological: M-M-R®IIBiological: Varivax®Biological: Meningitec®Biological: PedvaxHIB®
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2018-07-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1104
- Registration Number
- NCT00134719
- Locations
- 🇦🇺
GSK Investigational Site, Perth, Western Australia, Australia
Study of 2 Doses of Oral Live Attenuated Human Rotavirus (HRV) Vaccine for the Prophylaxis of Rotavirus Gastroenteritis
Phase 3
Completed
- Conditions
- Infections, Rotavirus
- First Posted Date
- 2005-08-25
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 150
- Registration Number
- NCT00134732
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath